Canandaigua National Bank & Trust Co. Has $257,000 Stock Position in The Cooper Companies, Inc. (NASDAQ:COO)

Canandaigua National Bank & Trust Co. reduced its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 17.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,333 shares of the medical device company’s stock after selling 497 shares during the period. Canandaigua National Bank & Trust Co.’s holdings in Cooper Companies were worth $257,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. boosted its position in Cooper Companies by 248.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock valued at $25,000 after buying an additional 174 shares during the last quarter. Covestor Ltd lifted its stake in shares of Cooper Companies by 305.9% in the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 208 shares during the period. Innealta Capital LLC acquired a new position in shares of Cooper Companies in the 2nd quarter valued at $25,000. Crewe Advisors LLC raised its stake in Cooper Companies by 286.4% during the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after buying an additional 252 shares during the period. Finally, Clearstead Trust LLC acquired a new stake in Cooper Companies during the 1st quarter worth $36,000. 24.39% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Albert G. White III sold 114,992 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the sale, the chief executive officer now owns 165,273 shares of the company’s stock, valued at $18,267,624.69. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Cooper Companies news, CFO Brian G. Andrews sold 24,788 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the sale, the chief financial officer now owns 6,614 shares of the company’s stock, valued at approximately $700,422.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Albert G. White III sold 114,992 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the sale, the chief executive officer now directly owns 165,273 shares in the company, valued at $18,267,624.69. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently commented on COO. Piper Sandler raised their price objective on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Stifel Nicolaus reissued a “buy” rating and issued a $115.00 price target (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Wells Fargo & Company lifted their price target on Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Jefferies Financial Group raised Cooper Companies from a “hold” rating to a “buy” rating and lifted their price target for the company from $107.00 to $115.00 in a research note on Tuesday, July 16th. Finally, Robert W. Baird lifted their price target on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Cooper Companies presently has a consensus rating of “Moderate Buy” and an average price target of $115.00.

Cooper Companies Stock Down 1.0 %

NASDAQ COO opened at $105.92 on Friday. The company has a current ratio of 1.99, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. The Cooper Companies, Inc. has a 1-year low of $75.93 and a 1-year high of $112.38. The company has a 50 day moving average of $101.43 and a 200-day moving average of $96.03. The company has a market cap of $21.09 billion, a price-to-earnings ratio of 62.31, a PEG ratio of 2.63 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. During the same period in the previous year, the business earned $0.84 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis. On average, equities research analysts expect that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.